$25.990
+0.081 (+0.31%)At close
Price Predictions
Open in app to unlock longer-horizon forecasts.
AKTS Prediction & Forecast by Similar Chart Analysis
Alphio's AKTS stock price prediction model matches the current Aktis Oncology Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $25.82 (-0.65%). The 1-week path is $26.08 (+0.36%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.
Should I Buy Aktis Oncology Inc Stock?
Aktis Oncology (AKTS) is a good buy right now due to its current price of $25.78, which is significantly lower than the analyst price target of $40 set by Raymond James, indicating a potential upside of 55%. Additionally, the stock has shown a positive momentum with a 5-day change of +7.10% and a 20-day change of +16.81%. The main risk is the negative net income reported at -24,144,000 USD for Q2 2026, which reflects ongoing financial challenges.
AKTS stock price ended at $25.99 on Tuesday, after rising +0.31%
Aktis Oncology Inc (AKTS) last closed at $25.99, gaining +0.31%. These facts feed the 1-day and 1-week AKTS price prediction above.
Analyst Consensus
Aktis Oncology Inc (AKTS): 3 buy, 0 hold, 0 sell. Outlook: Strong Buy.
Sell / Buy
Technical signals summary based on buy and sell indicators. The gauge shows the overall market view.
Forecast Drivers
Aktis Oncology Inc (AKTS) forecast drivers combine similar chart patterns, seasonality, and moving averages.
Similar patterns
Bullish
Seasonality
Bearish
SMA 20
Bullish
SMA 200
Bullish
Similar Chart Patterns
Stocks whose recent price path most closely matches AKTS, ranked by similarity.
Seasonality analysis for AKTS
Historically the probability of a positive September return for AKTS is 4.76%. August offers the highest probability of a positive month at 46.51%, while January is the weakest seasonal window. Alphio blends this calendar with technical signals and similar chart pattern matching before it writes the forecast.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.